Developer docs
API playgroundTry for free, no card

Search company profiles

AIRNA

Full company profile

uuid000043m

Namestring
AIRNA
Legal namestring
AIRNA Corporation
Websiteurl
airna.com
Company typeenum
Private
Founded yearint
2021
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA editing therapeutics, ADAR-mediated editing, oligonucleotide drug development, rare disease therapeutics, cardiometabolic drug discovery
Industry6 codes
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAJ
RNA Therapeutics Regulatory, Quality & Pharmacovigilance (GxP, comparability, post-market)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
RNA Editing Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1RNA Editing Therapeutic Development and Commercialization
TypeOne Time License
Description

As a clinical-stage biotech, AIRNA generates value through the development and potential commercialization of RNA editing therapeutics. The company is advancing AIR-001 through Phase 1/2 clinical trials for AATD, with a broader pipeline of cardiometabolic and rare disease programs in development. Revenue will derive from product sales upon regulatory approval, with potential for co-development, licensing, or partnership deals for specific programs or territories. The company also seeks strategic collaborations to extend its platform capabilities into therapeutic areas of mutual interest.

airna.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

AIRNA is a clinical-stage biotech developing RNA editing therapeutics through its proprietary RESTORE+ platform, which uses engineered antisense oligonucleotides to recruit endogenous ADAR proteins for precise A-to-I (read as G) RNA edits without altering DNA. The lead candidate, AIR-001, is in Phase 1 trials for alpha-1 antitrypsin deficiency (AATD), with a pipeline targeting cardiometabolic diseases such as cardiovascular disease and LDL cholesterol reduction.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Up to 59% precise RNA editing in vivo with AIR-001 in a mouse model of AATD, corresponding to >40 µM corrected M-AAT protein in serum and 70 µM total AAT
+5 more records
Product overview1 text field

AIRNA is a clinical-stage biotech company developing RNA-editing therapeutics through its proprietary RESTORE+ platform. The company's lead product candidate is AIR-001, an RNA editing therapy for alpha-1 antitrypsin deficiency (AATD) currently in Phase 1 clinical trials. AIRNA is also advancing a pipeline of cardiometabolic programs targeting cardiovascular disease through protective variant introduction, as well as additional rare genetic disorder programs. The platform leverages adenosine deaminase acting on RNA (ADAR) to make precise edits to RNA without altering DNA.

Product and service3 records
1AIR-001
CategoryRNA editing therapeutic candidate
Description

AIR-001 is AIRNA's lead GalNAc-conjugated RNA editing oligonucleotide therapeutic candidate for AATD, designed to repair the disease-causing PiZ mutation (G-to-A) at the RNA level and restore functional M-AAT protein production. Administered subcutaneously and supported by up to 59% in vivo RNA editing in preclinical models, with no observed off-target edits.

2RESTORE+ Platform
CategoryRNA editing technology platform
Description

RESTORE+ is AIRNA's proprietary ADAR-mediated RNA editing platform. It uses engineered antisense oligonucleotides to recruit naturally occurring human ADAR proteins to make precise single-letter A-to-I (read as G) corrections in RNA, without permanently altering DNA. The platform supports best-in-class editing efficiency, optimal safety, patient-friendly subcutaneous administration, and reversible, repeatable dosing.

3Cardiometabolic RNA-Editing Programs (LDLR, ApoB)
CategoryCardiometabolic therapeutic pipeline
Description

AIRNA's preclinical pipeline programs for cardiometabolic disease that introduce protective cardiovascular variants identified through human genetics. The LDLR program targets LDL receptor editing for LDL cholesterol reduction, and the ApoB program targets apolipoprotein B to lower LDL cholesterol without hepatotoxicity.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFoundational Co-Founder InstitutionTypeStrategic or Co-development Partner
Description

Co-founded by Thorsten Stafforst, PhD from the University of Tübingen, who pioneered the ADAR RNA editing approach. The university's research underpins the RESTORE+ platform technology. Deep ongoing research collaboration through Tübingen-based R&D operations.

Strategic tierFoundational Co-Founder InstitutionTypeStrategic or Co-development Partner
Description

Co-founded by Jin Billy Li, PhD from Stanford University, who made key contributions to ADAR RNA editing science. Represents an academic collaboration providing foundational IP and continued scientific advisory through co-founder relationship.

3Strategic Collaborators (unspecified)
Strategic tierExploratory/Partnerships SoughtTypeStrategic or Co-development Partner
Description

AIRNA states it has deep expertise in precision RNA editing therapeutics across a range of genetically tractable disease targets and is actively seeking strategic collaborations to extend these capabilities to therapeutic areas of mutual interest. Contact: partnership@airna.com

airna.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Verve Therapeutics develops in vivo gene editing therapies for cardiovascular disease, including LDL cholesterol reduction. Its cardiometabolic gene editing programs directly overlap with AIRNA's LDLR and ApoB pipeline programs, though using a different editing modality.

TypeDirect peer
Description

Arrowhead Pharmaceuticals develops RNAi-based therapeutics using TRiM platform with multiple clinical-stage programs targeting liver and other tissues. It is a direct peer in oligonucleotide-based genetic medicines with cardiometabolic and rare disease programs.

TypeDirect peer
Description

Korro Bio is a clinical-stage biotech developing ADAR-mediated RNA editing therapeutics for genetic diseases, including alpha-1 antitrypsin deficiency. It is the most directly comparable company to AIRNA, pursuing the same modality, similar target tissues, and overlapping indications.

TypeEmerging player
Description

Beam Therapeutics is a clinical-stage company developing base editing therapies, which like ADAR-mediated RNA editing enable precise single-letter genetic corrections without double-strand breaks. It represents an adjacent editing modality pursuing overlapping genetic disease indications.

TypeEmerging player
Description

Tenaya Therapeutics develops genetic medicines for heart disease using gene therapy, gene editing, and cellular approaches. Its cardiometabolic focus overlaps with AIRNA's LDLR and ApoB programs, though using different modalities and delivery approaches.

TypeDirect peer
Description

Wave Life Sciences develops RNA-based therapeutics including RNA editing programs (AIMer platform) using ADAR-mediated editing, as well as siRNA and other oligonucleotide modalities. It is a direct competitor in the RNA editing space targeting similar rare and neurological diseases.

TypeDirect peer
Description

Ascidian Therapeutics (acquired by Roche in 2024) developed RNA editing therapeutics for neurological and other genetic diseases using an exon editing approach. It represents a direct competitor in the RNA editing modality space targeting rare diseases.

TypeDirect peer
Description

ProQR Therapeutics develops RNA-editing oligonucleotide therapies (Axiomer platform) that leverage ADAR for A-to-I editing. It targets rare genetic diseases and shares AIRNA's RNA editing mechanism and rare-disease commercial focus.

TypeBroad incumbent
Description

Alnylam is the commercial leader in RNAi therapeutics with multiple approved products and a deep pipeline. As a broader incumbent in RNA-targeted modalities, it shares AIRNA's liver-targeted oligonucleotide delivery approach (GalNAc) and rare-disease commercial infrastructure.

TypeBroad incumbent
Description

Ionis is the leading antisense oligonucleotide (ASO) therapeutics company with multiple approved products and a broad pipeline. AIRNA's guide oligonucleotides are ASOs, making Ionis a relevant broad incumbent in the underlying chemistry and delivery platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AIRNA

RNA Editing Therapeuticsairna.com

AIRNA firmographics

Firmographics
Name
AIRNA
Legal name
AIRNA Corporation
Website
https://airna.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

AIRNA industry classification

Industry
Product category
RNA Editing Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAJ
RNA Therapeutics Regulatory, Quality & Pharmacovigilance (GxP, comparability, post-market)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • RNA editing therapeutics
  • ADAR-mediated editing
  • Oligonucleotide drug development
  • Rare disease therapeutics
  • Cardiometabolic drug discovery

Where AIRNA is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

AIRNA business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. RNA Editing Therapeutic Development and Commercialization: As a clinical-stage biotech, AIRNA generates value through the development and potential commercialization of RNA editing therapeutics. The company is advancing AIR-001 through Phase 1/2 clinical trials for AATD, with a broader pipeline of cardiometabolic and rare disease programs in development. Revenue will derive from product sales upon regulatory approval, with potential for co-development, licensing, or partnership deals for specific programs or territories. The company also seeks strategic collaborations to extend its platform capabilities into therapeutic areas of mutual interest.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

AIRNA product offering

Product offering

Core offering

AIRNA is a clinical-stage biotech developing RNA editing therapeutics through its proprietary RESTORE+ platform, which uses engineered antisense oligonucleotides to recruit endogenous ADAR proteins for precise A-to-I (read as G) RNA edits without altering DNA. The lead candidate, AIR-001, is in Phase 1 trials for alpha-1 antitrypsin deficiency (AATD), with a pipeline targeting cardiometabolic diseases such as cardiovascular disease and LDL cholesterol reduction.

Product overview

AIRNA is a clinical-stage biotech company developing RNA-editing therapeutics through its proprietary RESTORE+ platform. The company's lead product candidate is AIR-001, an RNA editing therapy for alpha-1 antitrypsin deficiency (AATD) currently in Phase 1 clinical trials. AIRNA is also advancing a pipeline of cardiometabolic programs targeting cardiovascular disease through protective variant introduction, as well as additional rare genetic disorder programs. The platform leverages adenosine deaminase acting on RNA (ADAR) to make precise edits to RNA without altering DNA.

Differentiator

Problem solved

Functional benefit

Products and services

  • AIR-001 AIR-001 is AIRNA's lead GalNAc-conjugated RNA editing oligonucleotide therapeutic candidate for AATD, designed to repair the disease-causing PiZ mutation (G-to-A) at the RNA level and restore functional M-AAT protein production. Administered subcutaneously and supported by up to 59% in vivo RNA editing in preclinical models, with no observed off-target edits.
  • RESTORE+ Platform RESTORE+ is AIRNA's proprietary ADAR-mediated RNA editing platform. It uses engineered antisense oligonucleotides to recruit naturally occurring human ADAR proteins to make precise single-letter A-to-I (read as G) corrections in RNA, without permanently altering DNA. The platform supports best-in-class editing efficiency, optimal safety, patient-friendly subcutaneous administration, and reversible, repeatable dosing.
  • Cardiometabolic RNA-Editing Programs (LDLR, ApoB) AIRNA's preclinical pipeline programs for cardiometabolic disease that introduce protective cardiovascular variants identified through human genetics. The LDLR program targets LDL receptor editing for LDL cholesterol reduction, and the ApoB program targets apolipoprotein B to lower LDL cholesterol without hepatotoxicity.

Quantifiable outcome

  • Up to 59% precise RNA editing in vivo with AIR-001 in a mouse model of AATD, corresponding to >40 µM corrected M-AAT protein in serum and 70 µM total AAT
  • +5 more outcomes

Companies that use AIRNA

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

AIRNA technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

AIRNA partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered foundational co-founder institution and exploratory/partnerships sought.

  • University of Tübingenfoundational co-founder institutionStrategic or Co-development PartnerCo-founded by Thorsten Stafforst, PhD from the University of Tübingen, who pioneered the ADAR RNA editing approach. The university's research underpins the RESTORE+ platform technology. Deep ongoing research collaboration through Tübingen-based R&D operations.
  • Stanford Universityfoundational co-founder institutionStrategic or Co-development PartnerCo-founded by Jin Billy Li, PhD from Stanford University, who made key contributions to ADAR RNA editing science. Represents an academic collaboration providing foundational IP and continued scientific advisory through co-founder relationship.
  • Strategic Collaborators (unspecified)exploratory/partnerships soughtStrategic or Co-development PartnerAIRNA states it has deep expertise in precision RNA editing therapeutics across a range of genetically tractable disease targets and is actively seeking strategic collaborations to extend these capabilities to therapeutic areas of mutual interest. Contact: partnership@airna.com

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

AIRNA competitors and assessment

Company assessment

Emerging players

  • Verve Therapeutics: Verve Therapeutics develops in vivo gene editing therapies for cardiovascular disease, including LDL cholesterol reduction. Its cardiometabolic gene editing programs directly overlap with AIRNA's LDLR and ApoB pipeline programs, though using a different editing modality.
  • Beam Therapeutics: Beam Therapeutics is a clinical-stage company developing base editing therapies, which like ADAR-mediated RNA editing enable precise single-letter genetic corrections without double-strand breaks. It represents an adjacent editing modality pursuing overlapping genetic disease indications.
  • Tenaya Therapeutics: Tenaya Therapeutics develops genetic medicines for heart disease using gene therapy, gene editing, and cellular approaches. Its cardiometabolic focus overlaps with AIRNA's LDLR and ApoB programs, though using different modalities and delivery approaches.

Direct peers

  • Arrowhead Pharmaceuticals: Arrowhead Pharmaceuticals develops RNAi-based therapeutics using TRiM platform with multiple clinical-stage programs targeting liver and other tissues. It is a direct peer in oligonucleotide-based genetic medicines with cardiometabolic and rare disease programs.
  • Korro Bio: Korro Bio is a clinical-stage biotech developing ADAR-mediated RNA editing therapeutics for genetic diseases, including alpha-1 antitrypsin deficiency. It is the most directly comparable company to AIRNA, pursuing the same modality, similar target tissues, and overlapping indications.
  • Wave Life Sciences: Wave Life Sciences develops RNA-based therapeutics including RNA editing programs (AIMer platform) using ADAR-mediated editing, as well as siRNA and other oligonucleotide modalities. It is a direct competitor in the RNA editing space targeting similar rare and neurological diseases.
  • Ascidian Therapeutics: Ascidian Therapeutics (acquired by Roche in 2024) developed RNA editing therapeutics for neurological and other genetic diseases using an exon editing approach. It represents a direct competitor in the RNA editing modality space targeting rare diseases.
  • ProQR Therapeutics: ProQR Therapeutics develops RNA-editing oligonucleotide therapies (Axiomer platform) that leverage ADAR for A-to-I editing. It targets rare genetic diseases and shares AIRNA's RNA editing mechanism and rare-disease commercial focus.

Broad incumbents

  • Alnylam Pharmaceuticals: Alnylam is the commercial leader in RNAi therapeutics with multiple approved products and a deep pipeline. As a broader incumbent in RNA-targeted modalities, it shares AIRNA's liver-targeted oligonucleotide delivery approach (GalNAc) and rare-disease commercial infrastructure.
  • Ionis Pharmaceuticals: Ionis is the leading antisense oligonucleotide (ASO) therapeutics company with multiple approved products and a broad pipeline. AIRNA's guide oligonucleotides are ASOs, making Ionis a relevant broad incumbent in the underlying chemistry and delivery platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

AIRNA social profiles

Digital presence

AIRNA compliance and trust

Trust signal

Compliance2 records

AIRNA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AIRNA leadership team

Management profile

Number of profiles

Profiles11 records

AIRNA subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

AIRNA funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AIRNA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AIRNA

What does AIRNA do?

AIRNA is a clinical-stage biotech developing RNA editing therapeutics through its proprietary RESTORE+ platform, which uses engineered antisense oligonucleotides to recruit endogenous ADAR proteins for precise A-to-I (read as G) RNA edits without altering DNA. The lead candidate, AIR-001, is in Phase 1 trials for alpha-1 antitrypsin deficiency (AATD), with a pipeline targeting cardiometabolic diseases such as cardiovascular disease and LDL cholesterol reduction.

Is AIRNA a public or private company?

AIRNA is a private company. It is classified as venture growth investor backed and is currently operating.

When was AIRNA founded?

AIRNA was founded in 2021. It employs 51 to 100 people.

Where is AIRNA based?

AIRNA is headquartered in Cambridge, United States, in the North America region.

How does AIRNA make money?

One revenue line is on record: RNA Editing Therapeutic Development and Commercialization.

Who are AIRNA's main competitors?

Emerging players on record are Verve Therapeutics, Beam Therapeutics and Tenaya Therapeutics. Direct peers are Arrowhead Pharmaceuticals, Korro Bio, Wave Life Sciences, Ascidian Therapeutics and ProQR Therapeutics. Broad incumbents are Alnylam Pharmaceuticals and Ionis Pharmaceuticals.

Does AIRNA have an API?

No public API is recorded for AIRNA.

What industry is AIRNA in?

AIRNA's product category is RNA Editing Therapeutics. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAADAE, RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry). Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
pharmaphorumMoonLake secures $500m for lead drug, plus other financingsMoonLake Immunotherapeutics secured up to $500 million in non-dilutive financing from Hercules Capital to advance its lead drug sonelokimab. The Swiss biotech has $448 million in cash reserves and plans to launch the drug in 2027. The financing also covers additional financings for AIRNA, Atsena, and Neurona.Business Wire BlogAIRNA Appoints Industry Veteran Todd Bazemore as President and CEO to Drive the Next Stage of Company GrowthAIRNA appointed Todd Bazemore as President and CEO, bringing over 30 years of biotech leadership experience. He will lead the company's RNA-editing pipeline, including its lead program AIR-001 for alpha-1 antitrypsin deficiency. Bazemore previously served as CEO of Kala Bio and President of U.S. Operations at Santhera Pharmaceuticals.BioSpaceAIRNA Presents New Preclinical Data on AATD Therapeutic Candidate AIR-001 and Cardiometabolic RNA-Editing Programs at ASGCTAIRNA presented preclinical data on AIR-001 for alpha-1 antitrypsin deficiency at ASGCT, showing up to 59% RNA editing and 40 µM functional M-AAT in a mouse model. The company also shared cardiometabolic RNA-editing data, including a 92% LDL cholesterol reduction in a humanized mouse model. AIR-001 is in a Phase 1 clinical trial.Business Wire BlogAIRNA Presents New Preclinical Data on AATD Therapeutic Candidate AIR-001 and Cardiometabolic RNA-Editing Programs at ASGCTAIRNA presented preclinical data on AIR-001 for alpha-1 antitrypsin deficiency at ASGCT, showing up to 59% RNA editing and 40 µM functional M-AAT in a mouse model. The company also reported RNA-editing programs targeting LDLR and ApoB, achieving a 92% LDL cholesterol reduction in a humanized mouse model.BioSpaceAIRNA to Present New Preclinical Data on RNA-Editing Therapeutic Pipeline at ASGCT Annual MeetingAIRNA will present new preclinical data on its RNA-editing therapeutics, including lead candidate AIR-001 for alpha-1 antitrypsin deficiency and cardiometabolic portfolio, at the 2026 ASGCT Annual Meeting. The oral presentation covers in vivo data on AIR-001, currently in Phase 1 clinical trial, and a poster shares proof-of-concept studies for introducing protective variants in LDLR and APOB.Longevity.TechnologyAIRNA doses first patient in RNA-editing trialAIRNA began dosing its first patient in a Phase 1 trial of AIR-001, an RNA-editing therapy for alpha-1 antitrypsin deficiency. The trial, called RepAIR1, enrolls about 54 patients across 11 countries, with the FDA granting orphan drug designation. The company aims to adjust dosing over time.Longevity.TechnologyAirna doses first patient in Phase 1 trial of AIR-001 for AATDAirna announced the first patient has been dosed in the global Phase 1 trial of AIR-001, its RNA-editing therapeutic for alpha-1 antitrypsin deficiency. The open-label RepAIR1 study is planned to enroll about 54 patients and has received regulatory authorization in multiple countries. The U.S. FDA has granted orphan drug designation to AIR-001.BioSpaceAIRNA Announces First Patient Dosed in Phase 1 Trial of AIR-001, Potential Best-in-Class RNA-Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)AIRNA announced that the first patient has been dosed in the global Phase 1 clinical trial of AIR-001, its RNA-editing therapy candidate for alpha-1 antitrypsin deficiency (AATD). The company also received Orphan Drug Designation from the FDA for AIR-001, which is designed to correct the disease-causing PiZ mutation at the RNA level and address both lung and liver manifestations of AATD. The trial, named RepAIR1, will enroll approximately 54 patients at an estimated 20 sites across 11 countries, with current enrollment underway in Australia and the United Kingdom.Bio-itworldFollow the Money: Cancer Platform Expansion, Wearable Device for Metabolic Health, MoreBio-IT World reports on a series of significant financing rounds in the biotech and healthcare sectors, led by Caris Life Sciences closing a $168 million growth capital round for its cancer platform expansion. Other major transactions include AIRNA securing $155 million for RNA editor clinical trials and Atsena Therapeutics raising $150 million for ocular gene therapy programs. These investments collectively support the development of novel therapies, diagnostic assays, and medical devices across various disease areas.VC News DailyAIRNA Scores $155 Million Series BAIRNA closed an oversubscribed $155 million Series B financing led by Venrock Healthcare Capital Partners. The company will use the proceeds to advance its lead RNA editing product candidate AIR-001 for AATD into a Phase 1/2 clinical trial and develop a pipeline of RNA-editing medicines for cardiometabolic and other diseases.